Thermo Fisher Scientific (NYSE:TMO) had its price objective raised by investment analysts at Barclays from $225.00 to $245.00 in a note issued to investors on Thursday, Marketbeat.com reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Barclays’ price objective suggests a potential upside of 10.18% from the stock’s previous close.
A number of other research analysts have also recently issued reports on TMO. Leerink Swann lifted their price objective on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research note on Monday, October 9th. Deutsche Bank set a $226.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Evercore ISI assumed coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $220.00 target price on the stock. Finally, BTIG Research assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, January 5th. They set a “buy” rating and a $230.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $220.50.
Shares of Thermo Fisher Scientific (NYSE TMO) traded down $1.75 during trading hours on Thursday, reaching $222.36. 1,897,309 shares of the company were exchanged, compared to its average volume of 1,606,986. The company has a market capitalization of $89,400.00, a PE ratio of 39.71, a price-to-earnings-growth ratio of 1.74 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. Thermo Fisher Scientific has a fifty-two week low of $150.23 and a fifty-two week high of $226.44.
In other news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now owns 252,577 shares in the company, valued at $47,582,981.03. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.49% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of the company. Covington Capital Management lifted its holdings in shares of Thermo Fisher Scientific by 0.9% during the second quarter. Covington Capital Management now owns 2,144 shares of the medical research company’s stock worth $374,000 after purchasing an additional 20 shares during the period. Investment Centers of America Inc. lifted its holdings in shares of Thermo Fisher Scientific by 1.6% during the second quarter. Investment Centers of America Inc. now owns 1,317 shares of the medical research company’s stock worth $230,000 after purchasing an additional 21 shares during the period. Fort Washington Investment Advisors Inc. OH lifted its holdings in shares of Thermo Fisher Scientific by 0.4% during the second quarter. Fort Washington Investment Advisors Inc. OH now owns 6,250 shares of the medical research company’s stock worth $1,090,000 after purchasing an additional 23 shares during the period. Bienville Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.6% during the second quarter. Bienville Capital Management LLC now owns 1,687 shares of the medical research company’s stock worth $295,000 after purchasing an additional 27 shares during the period. Finally, Pictet North America Advisors SA lifted its holdings in Thermo Fisher Scientific by 2.8% in the second quarter. Pictet North America Advisors SA now owns 1,764 shares of the medical research company’s stock valued at $308,000 after buying an additional 48 shares during the period. Institutional investors own 86.39% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first posted by American Market News and is owned by of American Market News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/01/thermo-fisher-scientific-tmo-given-new-245-00-price-target-at-barclays.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
